Close X
Attorney Spotlight

How did an interest in healthcare policy lead Robert Platt to a career in the law? Find out more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

Envision to Sell to KKR for $9.9 Billion

We represented Envision Healthcare Corporation (NYSE: EVHC) in its definitive agreement to sell to KKR in an all-cash transaction for $9.9 billion, including debt. KKR will pay $46 per Envision share in cash to buy the company, marking a 32 percent premium to the company's volume-weighted average share price from November 1, when Envision announced it was considering its options. The transaction is expected to close the fourth quarter of 2018. Read more


Envision Healthcare

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Six Things to Know Before Buying a Physician Practice spotlight

Dermatology, ophthalmology, radiology, urology…the list goes on. Yet, in any physician practice management transaction, there are six key considerations that apply and, if not carefully managed, can derail a transaction. Download the 6 Things to Know Before Buying a Physician Practice to keep your physician practice management transactions on track.

Click here to download the guide.

Attorney Spotlight: Shannon Wiley

March 5, 2018

Shannon Wiley spotlightTell us about your practice.

I practice healthcare law almost exclusively in the "specialty drug and device" space. A specialty drug or device is generally any drug therapy that requires special treatment — for example, it is really expensive (i.e. over $100,000 for treatment), for a rare disease, has an odd treatment regime, or is difficult to get reimbursed by insurance. I spend a lot of my time assisting with strategic development of business relationships, like limited drug distribution networks, patient service offerings between manufacturers and pharmacies, as well as mergers and acquisitions. This includes helping to develop the relationships in accordance with regulations drafting the associated contracts.

What is an interesting trend happening right now related to your field of practice?

The specialty pharmacy market ebbs and flows with regard to M&A activity; we are in a flow right now. We are seeing private equity and vertical strategic buyers have the most interest. Private equity funds often look to aggregate pharmacies to create an enterprise with a sum greater than its parts, while vertical strategics bank on market synergies to increase asset value. It is fascinating to be a part of those acquisitions and later integration activities. It provides great insight into industry economic and supply chain trends. 

You've attended the Asembia Specialty Pharmacy Summit for several years. What do you always look forward to and enjoy about this event? 

During Asembia, the entire specialty industry converges in one spot. It is great opportunity to catch up with many industry colleagues (and really friends) that I often only get to see a couple of times a year. I also get to meet new people and learn about their businesses, which is always a delight. Also, each conference really develops its own voice. After the first or second day, one starts to hear that voice and get a feel for what is on peoples' minds at an industry level. It's a deep dive that is an absolute must for giving clients the industry insight and staying current.


Related Professionals

Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.